



"Molecular Characterization of CD133⁺ Cells as a Progenitor of Cancer Stem Cells in Hepatocellular Carcinoma"

Thesis

Submitted in Partial Fulfillment for

M.Sc. Degree in Science

(Microbiology)

By

Enas Reda Ismail El-Sisi

(B.Sc. Microbiology, 2009)

Supervisors:

Prof. Dr. Ahmed Barakat Barakat Prof. Dr. Abdel Rahman Nabawy Zekri,

Professor of Virology, Microbiology Department, Faculty of Science, Ain Shams University Professor of Virology and Immunology, Cancer Biology Departement, National Cancer Institute Cairo University

Prof. Dr. Alaa El-Dien Ismail Abdel Motaleb

Professor of Surgery, Faculty of Medicine, Ain Shams University.

Department of Microbiology

Faculty of Science

Ain Shams University

2016





Approval Sheet

Name of student: Enas Reda Ismail El-Sisi

Title of thesis: "Molecular Characterization of CD133⁺ Cells as a Progenitor of Cancer Stem Cells in Hepatocellular Carcinoma"

Supervisors

Prof. Dr. Ahmed Barakat Barakat

Professor of Virology, Microbiology Department, Faculty of Science, Ain Shams University.

Prof. Dr. Abdel Rahman Nabawy Zekri

Professor of Virology and Immunology, Cancer Biology Department, National Cancer Institute, Cairo University.

Prof. Dr. Alaa El-Dien Ismail Abdel Motaleb

Professor of Surgery, Faculty of Medicine, Ain Shams University.

Reviewers

Prof. Dr. Mohamed Ali Saber

Professor of Biochemistry, Theodor Bilharz Research Institute.

Prof. Dr. Nagwa Mahmoud Sedky

Professor of Biotechnology, Faculty of Science, Al- Azhar University.

Prof. Dr. Ahmed Barakat Barakat

Professor of Virology, Microbiology Department, Faculty of Science, Ain Shams University.

Prof. Dr. Abdel Rahman Nabawy Zekri

Professor of Virology and Immunology, Cancer Biology Department, National Cancer Institute, Cairo University.

Date of examination: / / 2016

سبثانك لا علم لنا إلا ما تحلمتنا إنك أنت العليم اللاف PT AM SAAP SAA

Declaration

I certify that the thesis titled "Molecular Characterization of CD133⁺ Cells as a Progenitor of Cancer Stem Cells in Hepatocellular Carcinoma" is my own work. The work has not been presented elsewhere for assessment. Where material has been used from other sources it has properly acknowledged/referred.

	5	į	g	1			
					_		_

<u>ACKNOWLEDGEMENT</u>

First and foremost, I feel always indebted to Allah, the most beneficient and merciful, I can do nothing without Him

I would like to express my deep and sincere gratitude to my research supervisor, **Prof. Dr. Abdel Rahman N. Zekri**, for giving me the support to do research and for providing invaluable guidance throughout this research. His dynamism, vision, sincerity and motivation have deeply inspired me. It was a great privilege and honor to work and study under his guidance. I am extremely grateful for what he has offered me. I would also like to thank him for his empathy.

I am so grateful to **Prof. Dr. Ahmed Barakat Barakat** for his keen supervision, help, skillful cooperation and sincere guidance during the work. Actually he was more than supervisor, he was a teacher who inspired me and pushed me forward.

I am deeply indebted to **Prof. Dr. Alaa El-Dien Ismail Abd El-Motaleb** for his continuous help, warm encouragements and facilities offered by his help throughout the work.

I am extremely grateful to my family for their love, caring, support and sacrifices for education and preparing me for my future.

A deep thank to all my colleagues in virology and immunology unit for their assistance and support

Finally, my thanks go to all the people who have supported me to complete the research work directly or indirectly.

List of Contents

	Title	Page
Lis	st of Contents	I
	st of Tables	V
	st of Figures	VII
	st of Abbreviations	X 1
1. 2.		5
_,	2.1. The Liver	5
	2.1.1. Hepatocytes and hepatic lobule	5
	2.2. Liver cancer	6
	2.2.1. Primary liver cancer	6
	2.2.1.1. Hepatocellular carcinoma (HCC)	6
	2.2.1.2. Bile duct cancers (cholangiocarcinomas)	7
	2.2.1.3. Angiosarcomas and Hemangiosarcomas	7
	2.2.1.4. Hepatoblastoma	7
	2.2.2. Secondary liver cancer	7
	2.3. Epidemiology of HCC	7
	2.4. Incidence of HCC	8
	2.5. Risk factors for HCC	9
	2.5.1. Hepatitis B Virus	10
	2.5.2. Cirrhosis	11
	2.5.3. Hepatitis C virus	11
	2.5.3.1. Transmission of HCV	12
	2.5.3.2. HCV diagnostic tests	13
	2.5.3.3. Genomic organization for HCV	14
	2.5.3.4. Fate of HCV infection	16
	2.5.3.4.1. Hepatic manifestations	16
	2.5.3.4.1.1. Acute infection	16
	2.5.3.4.1.2. Chronic Hepatitis C	17
	2.5.3.4.1.3. Progression of Liver Fibrosis	18
	2.5.3.4.1.4. Cirrhosis	18
	2.5.3.4.1.5. Hepatocellular carcinoma (HCC)	19
	2.5.3.4.2. Extrahepatic manifestion	19
	2.5.4. Patient risk factors of HCC includes:	20

		2.5.4.1.	Gender	20
		2.5.4.2.	Race/ethnicity	21
	2.6.	Hepatoc	ellular carcinoma in Egypt	21
	2.7.	Stem ce	lls	23
		2.7.1. St	tem cells definition	23
		2.7.2. C	lasssification of stem cells	. 23
		2.7.2.1.	Based on Differentiation Potential	23
		2.7.2.2.	Stem Cell Classification Based on Origin	24
	2.	.8. Ca	ncer Stem Cells (CSC)	24
	2.	.8.1. Defi	nition	24
	2.	.8.2. Isola	tion of cancer stem cells:	25
		2.8.2.1	. Side population (SP) - (Hoechst 33342 dye staining)	25
		2.8.2.2	. Cell surface markers	25
		2.8.2.3	. Culture of nonadherent spheres:	26
	2.	.8.3. The	cancer stem cell theory:	. 26
	2.	.8.4. Do C	CSCs Arise From Stem Cells?	27
	2.9	. Liver	Stem Cells:	28
	2.	.9.1. Hepa	atocytes Have "Stem Cell" Properties	29
	2.	.9.2. Oval	/Liver Progenitor Cells	29
	2.	.9.3. Bone	e Marrow-Derived Stem Cells	31
	2.1	0. Cance	er stem cells in HCC:	. 31
	2.1	1. What	is CD133	33
	2.	.11.1. CD1	33 as a normal stem cell marker	34
	2.	.11.2. CD1	33 as a cancer stem cell marker	34
	2.1	2. Molec	cular machinery operating in normal and cancer stem cells	
		in live	т	35
	2.	.12.1. Notc	ch signaling pathway	35
	2.1	3. Micro	RNA (miRNA) Biogenesis and role in Hepatic cancer	
		stem c	eells	37
	2.	.13.1. The	Biogenesis of miRNA	37
	2.	.13.2. Biolo	ogical Roles of MicroRNAs	39
	2.	.13.3. MiR	NA and Cancer	39
	2.	.13.4. Hepa	atic Cancer Stem Cells and miRNA	40
3- PA	ATIE	NTS AND	METHODS	41

	3.1. Inclusion criteria of the	participants
	3.2. Exclusion criteria of the	e participants
	3.3. Assigned groups of the	included patients
	3.4. The laboratory investig	ations of the selected patients
	3.5. Other investigations of	the selected patients:
	3.6. Sample collection	•••••••••••••••••••••••••••••••••••••••
	3.7. Magnetic separation of	CD133 ⁺ cells
	3.7.1. Sample preparation	
	3.7.2. Magnetic labeling	
	3.7.3. Magnetic separation	
	3.8. Flow cytometry	
	3.9. Molecular profiling of	CD133 ⁺ cells
	3.9.1. The Human Stem Co	ell RT ² Profiler TM PCR Array
	3.9.1.1. RNA Extracti	ion
	3.9.1.2. RNA concent	ration and purity measurements:
	3.9.1.3. C-DNA synth	nesis
	3.9.1.4. Performing R	eal Time PCR
	3.9.1.5. Performing R	eal-Time PCR Detection
	3.9.2. Custom miRNA RT	2 Profiler PCR Array
	3.9.2.1. C-DNA synth	nesis
	3.9.2.2. Performing R	eal-Time PCR
	3.9.2.3. Performing P	CR detection
	3.9.2.4. Data Analysis	s: ΔΔCt Method
4.	RESULTS	
	4.1. Demographic features an	nd clinical data of the studied participants
	4.2. Purity of separated CD13	33 ⁺ subpopulation
	4.3. Molecular profiling of C	CD133 ⁺ cells using The Human Stem Cell
	RT ² Profiler TM PCR Arra	ay
	4.3.1. Molecular profiling of	f CD133 ⁺ cells separated from peripheral
	blood (circulating CD	133 ⁺ cells)
	4.3.1.1. Differentially e	expresses genes in the circulating CD133 ⁺
	cells of CHC g	roup vs. control group
	4.3.1.2. Differentially e	expressed genes in the circulating CD133 ⁺
	cells of LC gro	up vs. control group

	4.3.1.3.	Differentially expresses genes in the circulating CD133 ⁺
		cells of HCC group vs. control group
	4.3.1.4.	Differential expressed genes in the circulating CD133 ⁺
		cells of HCC group versus CHC group
	4.3.1.5.	Differentially expressed genes in the circulating CD133 ⁺
		cells of HCC group versus LC group
	4.3.2. Tl	ne molecular profiling of CD133 ⁺ cells separated from
	bo	one marrow (BM CD133 ⁺ cells)
	4.3.2.1.	Differentially expressed genes in CD133 ⁺ cells from
		BM of LC group versus control group
	4.4. miRNA	A profiling of CD133 ⁺ cells using miRNA PCR custom
	array	81
	4.4.1. miR	NA profiling of CD133 ⁺ cells separated from peripheral
	bloc	od (circulating CD133 ⁺ cells)
	4.4.1.1.	Differentially expressed miRNAs in circulating CD133 ⁺
		cells of CHC group versus control group
	4.4.1.2.	Differentially expressed miRNAs in the circulating
		CD133 ⁺ cells of LC group versus control group
	4.4.1.3.	Differentially expressed miRNAs in the circulating
		CD133 ⁺ cells of HCC group versus control group 85
	4.4.1.4.	Differentially expressed miRNAs in the circulating
		CD133 ⁺ cells of HCC group versus CHC group
	4.4.1.5.	Differentially expressed miRNAs in the circulating
		CD133 ⁺ cells of HCC group versus LC group
	4.4.2. miR	NA profiling of CD133 ⁺ cells separated from (BM)
	4.4.2.1.	Differentially expressed miRNAs in CD133 ⁺ cells from
		BM of LC group versus control group
5.	DISCUSSION	97
6.	SUMMARY	AND CONCLUSION
7.	REFERENC	ES 11
-		11

List of Tables

Number	Table title	Page
Table (A)	HCV proteins and their function in the viral life cycle	15
Table (B)	Protocol of experimental RT cocktail (for the human stem cell PCR array)	51
Table (C)	Gene table of the human stem cell PCR array	52
Table (D)	protocol for experimental cocktail of PCR (for human stem cell PCR array):	56
Table (E)	PCR cycling protocol (for stem cell PCR array human system)	56
Table (F)	Protocol of experimental RT cocktail (for custom miRNA array)	57
Table (G)	miRNA ID with their Catalog Number	58
Table (H)	Protocol of experimental cocktail for PCR (for miRNA PCR custom array)	59
Table (I)	PCR cycling protocol (for miRNA PCR custom array)	60
Table (1)	Demographic features and clinical data of the studied participants	65
Table (2)	The differentially expressed genes in the circulating CD133 ⁺ cells of CHC group versus control group.	67
Table (3)	The differentially expressed genes in the circulating CD133 ⁺ cells of LC group versus control group.	69
Table (4)	The differentially expressed genes in the circulating CD133 ⁺ cells of HCC group versus control group	71
Table (5)	The differentially expressed genes in the circulating CD133 ⁺ cells of the different studied groups (CHC, LC and HCC groups) versus control group	73

Table (6)	The differentially expressed genes in the circulating CD133 ⁺ of HCC group versus CHC group.	75
Table (7)	The differentially expressed genes in the circulating CD133 ⁺ in HCC group versus LC group	77
Table (8)	The differentially expressed genes in CD133 ⁺ cells from BM of LC group the control group	79
Table (9)	The differentially expressed miRNAs in the circulating CD133 ⁺ cells of CHC group versus the control group	81
Table (10)	The differentially expressed miRNAs in the circulating CD133 ⁺ cells of LC group versus control group	83
Table (11)	The differentially expressed miRNAs in the circulating CD133 ⁺ cells of HCC group versus control group	85
Table (12)	The differentially expressed miRNAs in the circulating CD133 ⁺ cells of the different groups (HCC, Cirrhotic, and Non- cirrhotic group) versus control group.	87
Table (13)	The differentially expressed miRNAs in the circulating CD133 ⁺ cells of CHC group versus the control group	89
Table (14)	The differentially expressed miRNAs in the circulating CD133 ⁺ cells of HCC group versus LC group	91
Table (15)	The differentially expressed miRNAs in CD133 ⁺ cells from BM of LC group versus the control group	95

List of Figures

		Page
Figure (A):	The hepatic lobule is the structural unit of the liver	6
Figure (B):	Map of age-standardized incidence rates (ASR) of HCC	9
Figure (C):	Figure (C): Risk factors for HCC	10
Figure (D):	The estimated prevalence of HCV infection and the distribution of HCV genotypes across the world	12
Figure (E):	The risk factors for hepatitis C acquisition	13
Figure (F):	Hepatitis C virus (HCV): model structure and genome organization	15
Figure (G)	Acute HCV infection with recovery	17
Figure (H)	Acute HCV infection evolving to chronic infection	17
Figure (I)	Natural history of HCV infection	20
Figure (J)	Incidence and mortality of HCC in Egyptian men	21
Figure (K)	Incidence and mortality of HCC in Egyptian women	22
Figure (L)	How Do Cancer Stem Cells Arise	28
Figure (M)	Depiction of liver progenitor cells (LPC) residing in the Canals of Herring (CoH) in the healthy liver tissue	30
Figure (N)	Hepatocarcinogenesis based on CSC theory	32

Figure (O)	Schematic representation of transmembrane glycoprotein, CD133	33
Figure (P)	JAG1 in cancer biology	37
Figure (Q)	Schematic overview of canonical miRNA biogenesis.	37
Figure (R)	Positive selection strategy using autoMACS Separator	46
Figure (S)	Array layout of RT² Profiler™ PCR Array Human Stem Cell (PAHS-405Z)	52
Figure (T)	Array layout table miRNA symbol and position information for six samples, 13 miRNA PCR array/ 96-well plate.	58
Figure (1)	Flow cytometry analysis demonstrating CD133 ⁺ cells purity	66
Figure (2)	Volcano plot shows the differentially expressed genes in the circulating CD133 ⁺ cells of CHC group (group 1) versus control group	68
Figure (3)	Volcano plot shows the differentially expressed genes in the circulating CD133 ⁺ cells of LC group (group 2) versus control group	70
Figure (4)	Volcano plot shows the differentially expressed genes in the circulating CD133 ⁺ cells of the HCC group (group 3) versus control group	72
Figure (5)	The clustergram shows the comparison between the expression level of the tested genes in the circulating CD133 ⁺ cells of the studied groups (CHC: group 1, LC: group 2, and HCC: group 3) versus the control group	74
Figure (6)	Volcano plot shows the differentially expressed genes in the circulating CD133 ⁺ cells of HCC group (group 1) versus CHC (control group)	76
Figure (7)	Volcano plot shows the differentially expressed genes in the circulating CD133 ⁺ cells of HCC group (group 1) versus LC group (control group)	78
Figure (8)	Volcano plot showing the differentially expressed genes in CD133 ⁺ cells from BM of LC group (group 1) versus control group	80
Figure (9)	Volcano plot shows the differentially expressed miRNAs in circulating CD133 ⁺ cells of CHC group versus control group	82
Figure (10)	The multi group plot provides line graph representation for differential expression of 13-miRNA sthe circulating CD133 ⁺ cells of CHC group versus the control group	82

Figure (11)	Volcano plot shows the differentially expressed miRNAs in circulating CD133 ⁺ cells of the LC group versus the control group.	84
Figure (12)	The multi group plot provides line graph representation for differential expression of 13-miRNAsthe circulating CD133 ⁺ cells of LC group versus the control group	84
Figure (13)	Volcano plot shows the differentially expressed miRNAs in the circulating CD133 ⁺ cells of HCC group versus control group	86
Figure (14)	The multi group plot provides line graph representation for differential expression of 13-miRNAsthe circulating CD133 cells of HCC group versus CHC group	86
Figure (15)	The clustergram shows the differential expression of the studied 13 miRNAs in CD133 ⁺ cells of the different studied groups (non- cirrhotic =group 1, cirrhotic group= group 2, and HCC = group 3) versus the control group	87
Figure (16)	The multi group plot provides both a bar chart and line graph representation for differential expression of 13-miRNAs in the circulating CD133 ⁺ cells of the studied three groups in comparison with control group.	88
Figure (17)	Volcano plot shows the differentially expressed miRNAs in the circulating CD133 ⁺ cells of HCC group versus CHC group	90
Figure (18)	The multi group plot provides line graph representation for differential expression of 13 miRNAs in the circulating CD133 ⁺ cells of HCC group versus CHC group	90
Figure (19)	Volcano plot shows the differentially expressed miRNAs in the circulating CD133 ⁺ cells of HCC group versus LC group	92
Figure (20)	The multi group plot provides line graph representation for differential expression of 13-miRNAs in the circulating CD133 cells of HCC group versus LC group	92
Figure (21)	Venn graph represented the differential expression of 13 miRNAs of the CD133 ⁺ of HCC groups in comparison with the control group, CHC group, and LC group.	93
Figure (22)	Suggested cartoon representing the relationship of significant overlapping miRNAs in CD133 ⁺ stem cells associated with hepatocarcinogenesis	94
Figure (23)	Volcano plot shows the differentially expressed miRNAs in CD133cells from BM of LC group (group 1) versus the control group	96
Figure (24)	The multi group plot provides line graph representation for differential expression of 13-miRNAsin CD133 ⁺ cells from BM of LC group (group 1) versus the control group	96

List of Abbreviations

ABC Adenosine triphosphate (ATP)-binding cassette

AC133 A glycosylation-dependent epitope of CD133 (epitope 1 of the

CD133)

ADAM10 A disintegrin and metalloproteinase domain-containing protein 10

AFP Alfa fetoprotein

AIDS Acquired immune deficiency syndrome

AKT Protein kinase B (PKB)
ALP Alkaline phosphatase
ALT Alanine aminotransferase
AML Acute myeloid leukemia

ASC Adult stem cells

ASR Age-standardized incidence rates

AST Aspartate aminotransferase BAK1 BCL2 Antagonist/Killer 1

BCL2 B-cell lymphoma 2
Bim Bcl-2-like protein 11

BM Bone marrow

BMI1 Proto-Oncogene, Polycomb Ring Finger

CCND1 Cycline D1

CD Cluster of differentiation

CDC42 Cell division control protein 42 homolog

CDH1 Cadherin 1

CDK4 Cyclin-dependent kinase 4
CDK6 Cyclin-dependent kinase 6

CDKN1B Cyclin-Dependent Kinase Inhibitor 1B **CDKN1C** Cyclin-Dependent Kinase Inhibitor 1C

cDNA Complementary DNA CDX2 Caudal type homeobox 2

CHC Chronic hepatitis c

CK Cytokeratin

CLD Chronic liver disease
CoH Canals of Herring
CSC Cancer stem cells

CSL CBF1, Suppressor of Hairless, Lag-1

Ct Cycle threshold

CYP3A4 Cytochrome P450, family 3, subfamily A, polypeptide 4

DGCR8 DiGeorge syndrome critical region gene 8

DHS Demographic and Health Survey